Research programme: hyperparathyroidism therapy - ProStrakan
Alternative Names: PSK 1594Latest Information Update: 18 Sep 2007
At a glance
- Originator ProStrakan
- Class
- Mechanism of Action Calcium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperparathyroidism
Most Recent Events
- 22 Dec 2006 Galapagos NV acquires ProStrakan's drug discovery unit
- 22 Dec 2006 Discontinued - Preclinical for Hyperparathyroidism in Europe (unspecified route)
- 17 Aug 2006 Preclinical trials in Hyperparathyroidism in Europe (unspecified route)